Drug-containing PLA implants and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9895447-B2
Application number	US-201715627389-A
Country	US
Kind code	B2
Filing date	Jun 19, 2017
Priority date	Jan 12, 2004
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

First claim

What is claimed is:

1. An implant comprising: a therapeutic drug and a polymer, said polymer comprising polylactic acid (PLA) and optionally polyglycolic acid (PGA) in a PLA:PGA molar ratio between 50:50 and 100:0, wherein said therapeutic drug is present in an amount of about 10%-30% (w/w), wherein the presence of said polymer in said implant extends the release duration of said therapeutic drug in a subject, and wherein said therapeutic drug is risperidone.

2. The implant of claim 1 , wherein said drug is present in an amount of about 30% (w/w).

3. The implant of claim 1 , wherein said drug is present in an amount of about 28% (w/w).

4. The implant of claim 1 , wherein said drug is present in an amount of about 20% (w/w).

5. The implant of claim 1 , wherein said drug is present in an amount of about 15% (w/w).

6. The implant of claim 1 , wherein said drug is present in an amount of about 10% (w/w).

7. The implant of claim 1 , wherein said polymer is a biodegradable polymer.

8. The implant of claim 1 , wherein said polymer is PLGA polymer.

9. The implant of claim 1 , wherein said PLA:PGA molar ratio is 75:25.

10. The implant of claim 1 , wherein said PLA:PGA molar ratio is 80:20.

11. The implant of claim 1 , wherein said PLA:PGA molar ratio is 85:15.

12. The implant of claim 1 , wherein said polymer is present in an amount of about 40-90% (w/w).

13. The implant of claim 1 , wherein said polymer is present in an amount of about 40-70% (w/w).

14. The implant of claim 1 , wherein said polymer is present in an amount of about 35-75% (w/w).

15. The implant of claim 1 , wherein said polymer is present in an amount of about 35% (w/w).

16. The implant of claim 1 , wherein said polymer is present in an amount of about 38% (w/w).

17. The implant of claim 1 , wherein said polymer is present in an amount of about 40% (w/w).

18. The implant of claim 1 , wherein said polymer is present in an amount of about 50% (w/w).

19. The implant of claim 1 , wherein said polymer is present in an amount of about 60% (w/w).

20. The implant of claim 1 , wherein said polymer is present in an amount of about 70% (w/w).

21. The implant of claim 1 , wherein said polymer is present in an amount of about 72% (w/w).

22. The implant of claim 1 , wherein said implant exhibits an inherent viscosity ranging from about 0.2 dl/g to about 0.9 dl/g.

23. The implant of claim 1 , wherein said implant is a subcutaneous implant.

24. An implant comprising: a therapeutic drug and a polymer, said polymer comprising polylactic acid (PLA) and polyglycolic acid (PGA) in a PLA:PGA molar ratio between 75:25 and 85:15, wherein said therapeutic drug is present in an amount of about 10%-60% (w/w) and said polymer is present in an amount of about 40-90% (w/w), wherein the presence of said polymer in said implant extends the release duration of said therapeutic drug in a subject, and wherein said therapeutic drug is risperidone.

Assignees

• Univ Pennsylvania

Inventors

• Siegel Steven
• Winey Karen

Classifications

• A61K47/34 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/549

  having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide · CPC title